Cedar Brook Corporate Center
4-B Cedar Brook Drive
Cranbury, NJ 08512
609 495 2200
Impiegati a tempo pieno: 33
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Carl Spana Ph.D.||Co-Founder, Pres, CEO & Director||943,25k||N/D||1962|
|Mr. Stephen T. Wills CPA, CPA, MST||CFO, COO, Exec. VP, Treasurer & Sec.||870,57k||N/D||1957|
|Burns McClellan||VP of Investor Relations||N/D||N/D||N/D|
|Mr. Stephen A. Slusher Esq.||Chief Legal Officer||N/D||N/D||N/D|
|Dr. Michael B. Raizman M.D.||Chief Medical Officer||N/D||N/D||N/D|
|Mr. James E. Hattersley||Sr. VP of Bus. Devel.||N/D||N/D||1960|
|Mr. John Dodd Ph.D.||Sr. VP of Preclinical Devel.||N/D||N/D||N/D|
|Mr. Robert Jordan||Sr. VP of Program Operations||N/D||N/D||N/D|
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
L'ISS Governance QualityScore di Palatin Technologies, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.